Andre Goy, MD, MS

Articles

Progress in Immunotherapy and Precision Medicine: Key Insights from JTCC at ASH 2024

December 18th 2024

Andre Goy, MD, discusses how progress in immunotherapy and precision medicine at ASH 2024 is shaping the future of cancer treatment, with key insights from the JTCC highlighting emerging therapies and their potential to improve patient outcomes through personalized approaches.

Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD

December 18th 2024

Andre Goy, MD, discusses top hematologic oncology research from the 2024 ASH Annual Meeting.

Dr Goy on Updated Data From ZUMA-2 With Brexu-Cel in MCL

March 27th 2024

Andre Goy, MD, discusses updated data from the phase 2 ZUMA-2 trial, highlighting the expanded-access ZUMA-18 study in MCL.

Dr Goy on the Rationale for Launching the ZUMA-18 Trial in Relapsed/Refractory MCL

February 13th 2024

Andre Goy, MD, discusses the evaluation of brexu-cel in the ZUMA-2 and expanded access ZUMA-18 trials in relapsed/refractory mantle cell lymphoma.

Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL

December 10th 2023

Andre Goy, MD, discusses outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma enrolled in the phase 2 ZUMA-2 trial and the expanded access ZUMA-18 study.

Dr. Goy on the Efficacy of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

March 10th 2021

Andre Goy, MD, discusses the efficacy of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma, as demonstrated in the phase 2 ZUMA-2 trial.

Dr. Goy on the Utility of NGS in Identifying Aggressive MCL Subtypes

October 1st 2020

Andre Goy, MD, MS, discusses the utility of next-generation sequencing in identifying aggressive subtypes of mantle cell lymphoma.

Dr. Goy on the Evolution of Treatment Selection in MCL

May 13th 2020

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

Dr. Goy on the Evolution of Treatment Selection in MCL

May 12th 2020

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

Dr. Goy on Research Efforts With BTK Inhibitors in MCL

May 12th 2020

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Dr. Goy on Research Efforts With BTK Inhibitors in MCL

May 11th 2020

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Dr. Goy on Comparing the Toxicity Profiles of BTK Inhibitors in MCL

May 8th 2020

Andre Goy, MD, MS, compares the toxicity profiles of available BTK inhibitors in mantle cell lymphoma.

Dr. Goy on the Progression of MCL Treatment

April 8th 2020

Andre Goy, MD, MS, discusses the paradigm shift in the treatment of patients with mantle cell lymphoma that has occurred over the past decade.

Dr. Goy on Combinations With Novel Agents in Relapsed/Refractory MCL

February 14th 2020

Andre Goy, MD, MS, discusses the utility of combinations with novel agents in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Dr. Goy the Evolution of Treatment in Relapsed/Refractory MCL

February 11th 2020

Andre Goy, MD, MS, discusses the evolution of treatment in relapsed/refractory mantle cell lymphoma.

Dr. Goy on the Results of the FLYER Trial in DLBCL

January 8th 2020

Andre Goy, MD, MS, chief, discusses the results of the multicenter FLYER trial in patients with diffuse large B-cell lymphoma.

Dr. Goy on Treating Older Patients With MCL

December 5th 2019

Andre Goy, MD, MS, discusses treatment approaches for older patients with mantle cell lymphoma.

Dr. Goy on the Significance of Becoming an NCI-Designated Cancer Center

May 15th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the significance of becoming a National Cancer Institute-designated cancer center.

Dr. Goy on Treatment Considerations in MCL

April 18th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses treatment considerations in mantle cell lymphoma.

Dr. Goy on Treatment Options for Patients With MCL

April 11th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses treatment options for patients with mantle cell lymphoma (MCL).